Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - warfarinum natríum - tafla - 3 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 150 mg

Unjoni Ewropea - Iżlandiż - EMA (European Medicines Agency)

teva b.v. - sjúklingum - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 og 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 og 5.

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - fesoterodinum fúmarat - forðatafla - 4 mg

Islanda - Iżlandiż - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - fesoterodinum fúmarat - forðatafla - 8 mg